raloxifene hydrochloride has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mack, GS | 1 |
| Basile, I; Gallud, A; Garcia, M; Gary-Bobo, M; Maynadier, M | 1 |
2 other study(ies) available for raloxifene hydrochloride and bortezomib
| Article | Year |
|---|---|
Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biotechnology; Boronic Acids; Bortezomib; Celecoxib; Cyanides; Drug Industry; Etanercept; Guanidines; Humans; Immunoglobulin G; Interleukin 1 Receptor Antagonist Protein; NF-kappa B; Patents as Topic; Protein C; Pyrazines; Pyrazoles; Raloxifene Hydrochloride; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Rituximab; Sialoglycoproteins; Sulfonamides; United States | 2006 |
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Leupeptins; MCF-7 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2016 |